These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38819334)

  • 1. Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.
    Petrie MC; Borlaug BA; Butler J; Davies MJ; Kitzman DW; Shah SJ; Verma S; Jensen TJ; Einfeldt MN; Liisberg K; Perna E; Sharma K; Ezekowitz JA; Fu M; Melenovský V; Ito H; Lelonek M; Kosiborod MN;
    J Am Coll Cardiol; 2024 Jul; 84(1):27-40. PubMed ID: 38819334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program.
    Schou M; Petrie MC; Borlaug BA; Butler J; Davies MJ; Kitzman DW; Shah SJ; Verma S; Patel S; Chinnakondepalli KM; Harring S; Abildstrøm SZ; Liisberg K; Kosiborod MN;
    J Am Coll Cardiol; 2024 Jul; 84(3):247-257. PubMed ID: 38913004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
    Butler J; Shah SJ; Petrie MC; Borlaug BA; Abildstrøm SZ; Davies MJ; Hovingh GK; Kitzman DW; Møller DV; Verma S; Einfeldt MN; Lindegaard ML; Rasmussen S; Abhayaratna W; Ahmed FZ; Ben-Gal T; Chopra V; Ezekowitz JA; Fu M; Ito H; Lelonek M; Melenovský V; Merkely B; Núñez J; Perna E; Schou M; Senni M; Sharma K; van der Meer P; Von Lewinski D; Wolf D; Kosiborod MN;
    Lancet; 2024 Apr; 403(10437):1635-1648. PubMed ID: 38599221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.
    Kosiborod MN; Verma S; Borlaug BA; Butler J; Davies MJ; Jon Jensen T; Rasmussen S; Erlang Marstrand P; Petrie MC; Shah SJ; Ito H; Schou M; Melenovský V; Abhayaratna W; Kitzman DW;
    Circulation; 2024 Jan; 149(3):204-216. PubMed ID: 37952180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
    Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
    JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials.
    Verma S; Butler J; Borlaug BA; Davies M; Kitzman DW; Shah SJ; Petrie MC; Barros E; Rönnbäck C; Vestergaard LS; Schou M; Ezekowitz JA; Sharma K; Patel S; Chinnakondepalli KM; Kosiborod MN;
    J Am Coll Cardiol; 2024 Aug; 84(9):773-785. PubMed ID: 38913003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction.
    Butler J; Abildstrøm SZ; Borlaug BA; Davies MJ; Kitzman DW; Petrie MC; Shah SJ; Verma S; Abhayaratna WP; Chopra V; Ezekowitz JA; Fu M; Ito H; Lelonek M; Núñez J; Perna E; Schou M; Senni M; van der Meer P; von Lewinski D; Wolf D; Altschul RL; Rasmussen S; Kosiborod MN
    J Am Coll Cardiol; 2023 Nov; 82(22):2087-2096. PubMed ID: 37993201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.
    Kosiborod MN; Abildstrøm SZ; Borlaug BA; Butler J; Christensen L; Davies M; Hovingh KG; Kitzman DW; Lindegaard ML; Møller DV; Shah SJ; Treppendahl MB; Verma S; Petrie MC
    JACC Heart Fail; 2023 Aug; 11(8 Pt 1):1000-1010. PubMed ID: 37294245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.
    Shah SJ; Sharma K; Borlaug BA; Butler J; Davies M; Kitzman DW; Petrie MC; Verma S; Patel S; Chinnakondepalli KM; Einfeldt MN; Jensen TJ; Rasmussen S; Asleh R; Ben-Gal T; Kosiborod MN
    Eur Heart J; 2024 Sep; 45(35):3254-3269. PubMed ID: 38739118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highest Obesity Category Associated With Largest Decrease in N-Terminal Pro-B-Type Natriuretic Peptide in Patients Hospitalized With Heart Failure With Preserved Ejection Fraction.
    Vaishnav J; Chasler JE; Lee YJ; Ndumele CE; Hu JR; Schulman SP; Russell SD; Sharma K
    J Am Heart Assoc; 2020 Aug; 9(15):e015738. PubMed ID: 32750299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
    Kosiborod MN; Petrie MC; Borlaug BA; Butler J; Davies MJ; Hovingh GK; Kitzman DW; Møller DV; Treppendahl MB; Verma S; Jensen TJ; Liisberg K; Lindegaard ML; Abhayaratna W; Ahmed FZ; Ben-Gal T; Chopra V; Ezekowitz JA; Fu M; Ito H; Lelonek M; Melenovský V; Merkely B; Núñez J; Perna E; Schou M; Senni M; Sharma K; van der Meer P; Von Lewinski D; Wolf D; Shah SJ;
    N Engl J Med; 2024 Apr; 390(15):1394-1407. PubMed ID: 38587233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-terminal pro-B-type natriuretic peptide post-discharge monitoring in the management of patients with heart failure and preserved ejection fraction - a randomized trial: The NICE study.
    Pascual-Figal DA; Hernández-Vicente A; Pastor-Pérez F; Martínez-Sellés M; Solé-González E; Alvarez-García J; García-Pavía P; Varela-Román A; Sánchez PL; Delgado JF; Noguera-Velasco JA; Bayes-Genis A;
    Eur J Heart Fail; 2024 Apr; 26(4):776-784. PubMed ID: 38606524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
    Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
    Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial).
    Patel RB; Vaduganathan M; Felker GM; Butler J; Redfield MM; Shah SJ
    Am J Cardiol; 2019 May; 123(10):1660-1666. PubMed ID: 30876658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
    Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
    J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
    Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
    Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
    Kosiborod MN; Abildstrøm SZ; Borlaug BA; Butler J; Rasmussen S; Davies M; Hovingh GK; Kitzman DW; Lindegaard ML; Møller DV; Shah SJ; Treppendahl MB; Verma S; Abhayaratna W; Ahmed FZ; Chopra V; Ezekowitz J; Fu M; Ito H; Lelonek M; Melenovsky V; Merkely B; Núñez J; Perna E; Schou M; Senni M; Sharma K; Van der Meer P; von Lewinski D; Wolf D; Petrie MC;
    N Engl J Med; 2023 Sep; 389(12):1069-1084. PubMed ID: 37622681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction.
    Salah K; Stienen S; Pinto YM; Eurlings LW; Metra M; Bayes-Genis A; Verdiani V; Tijssen JGP; Kok WE
    Heart; 2019 Aug; 105(15):1182-1189. PubMed ID: 30962192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.